Figure 2.
Kaplan–Meier plots demonstrating the relationship between biomarker positivity for combined biomarker positivity of amyloid-β and neurodegeneration (A/N) at study baseline (top section) and at endpoint (bottom section) with time (years) to progression to amnestic mild cognitive impairment in cognitively normal individuals.